Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Subjective Cognitive Decline is a Better Marker for Future Cognitive Decline in Females than in Males

Michael D. Oliver, View ORCID ProfileCassandra Morrison, View ORCID ProfileFarooq Kamal, Jillian Graham, View ORCID ProfileMahsa Dadar
doi: https://doi.org/10.1101/2022.08.18.22278960
Michael D. Oliver
1Department of Psychological Science and Neuroscience, Belmont University, Nashville, Tennessee, United States
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michael.oliver{at}belmont.edu
Cassandra Morrison
2McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
3Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cassandra Morrison
Farooq Kamal
4Department of Psychiatry, McGill University, Montreal, Quebec, Canada
5Douglas Mental Health University Institute, Montreal, Quebec, Canada
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Farooq Kamal
Jillian Graham
1Department of Psychological Science and Neuroscience, Belmont University, Nashville, Tennessee, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahsa Dadar
4Department of Psychiatry, McGill University, Montreal, Quebec, Canada
5Douglas Mental Health University Institute, Montreal, Quebec, Canada
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mahsa Dadar
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The identification of biomarkers and other mechanisms for early detection of Alzheimer’s disease is critical to the development and further advancement of therapies and interventions targeted at managing symptoms and tracking the pathophysiology of disease. The endorsement of subjective cognitive decline (SCD) has emerged as a potential indicator of early change in cognitive status that may be predictive of future impairment at a time when measurable declines in neuropsychological performance cannot be detected. While there are numerous findings revealing sex differences in the prevalence of Alzheimer’s disease, there is a paucity of research examining sex differences in SCD. Therefore, the goal of this project is to determine if the relationship between the endorsement of SCD and future cognitive changes differ as a function of biological sex.

Methods A sample of 3019 male and female healthy older adults (2188 without SCD, 831 with SCD), with a mean follow-up time of 5.7 years, were included from the Rush Alzheimer’s Disease Center Research Sharing Hub. Linear regressions were performed to determine group differences in baseline cognitive scores, while linear mixed effects models were computed to determine group differences in the rate of cognitive change over time.

Results Individuals endorsing SCD had significantly lower baseline cognitive scores and increased rates of decline in all cognitive domains compared to those without SCD. Males exhibited significantly lower scores in baseline performance in global cognition, episodic memory, semantic memory, and perceptual speed regardless of SCD classification. Females with SCD were found to decline at significantly faster rates than both males with SCD and males and females without SCD in all cognitive domains over 15-year follow-up.

Conclusions SCD is related to lower baseline cognitive performance and faster cognitive decline compared to those who do not endorse SCD. Females with SCD have the fastest rate of decline suggesting that SCD may be more predictive of future decline in females than in males. Therapeutic interventions targeting SCD in females may aid in the mitigation of sex disparities in AD prevalence.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Dr. Morrison is supported by a postdoctoral fellowship from Canadian Institutes of Health Research, Funding Reference Number: MFE-176608. Dr. Dadar reports receiving research funding from the Healthy Brains for Healthy Lives (HBHL), Alzheimer Society Research Program (ASRP), and Douglas Research Centre (DRC).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This stud uses only data obtained from a public database. Written data request was submitted and approved, data was then downloaded from RUSH: https://www.radc.rush.edu/

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced are available online after a written request and application is made at https://www.radc.rush.edu/

https://www.radc.rush.edu/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 22, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Subjective Cognitive Decline is a Better Marker for Future Cognitive Decline in Females than in Males
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Subjective Cognitive Decline is a Better Marker for Future Cognitive Decline in Females than in Males
Michael D. Oliver, Cassandra Morrison, Farooq Kamal, Jillian Graham, Mahsa Dadar
medRxiv 2022.08.18.22278960; doi: https://doi.org/10.1101/2022.08.18.22278960
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Subjective Cognitive Decline is a Better Marker for Future Cognitive Decline in Females than in Males
Michael D. Oliver, Cassandra Morrison, Farooq Kamal, Jillian Graham, Mahsa Dadar
medRxiv 2022.08.18.22278960; doi: https://doi.org/10.1101/2022.08.18.22278960

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Geriatric Medicine
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)